Blog
RSS FeedPosted by Michael Wonder on 08 Aug 2019
Decision for funding in the immunosuppressant, oncology, vasodilator and smoking cessation therapeutic areas
8 August 2019 - PHARMAC is pleased to announce the approval of a decision relating to medicines in the immunosuppressant, ...
Posted by Michael Wonder on 30 Jul 2019
Changes to funded vaccines in the National Immunisation Schedule
30 July 2019 - PHARMAC is pleased to announce decisions related to the National Immunisation Schedule that will take effect ...
Posted by Michael Wonder on 11 Jul 2019
Decision for funding in the neurology, immunosuppression, diabetes and anti-thrombotic therapy areas
11 July 2019 - PHARMAC is pleased to announce the approval of a decision relating to medicines in the neurology, ...
Posted by Michael Wonder on 06 Jun 2019
Decision to widen access to etanercept and award sole supply
6 June 2019 - PHARMAC has made a decision to make changes to the funding of etanercept, a biologic medicine ...
Posted by Michael Wonder on 08 May 2019
PTAC recommends the use of pembrolizumab as a first-line treatment for patients with advanced non-small cell lung cancer
8 May 2019 - The focus now shifts to when will the PTAC recommendation be implemented. ...
Posted by Michael Wonder on 06 May 2019
Decision to amend the distribution and access criteria for dasatinib (Sprycel)
3 May 2019 - PHARMAC has a made a decision to change the distribution arrangements and access criteria for the ...
Posted by Michael Wonder on 25 Apr 2019
No outcomes on breast cancer drugs Kadcyla and Ibrance yet, says PHARMAC
24 April 2019 - PHARMAC has reiterated that it has not yet made a decision on whether to fund two ...
Posted by Michael Wonder on 23 Apr 2019
PHARMAC rejects own experts' view on breast cancer drug
23 April 2019 - PHARMAC has refused funding for Kadcyla, an important drug that has recently had a high media ...
Posted by Michael Wonder on 23 Apr 2019
PHARMAC reportedly has rejected funding for breast cancer drug
23 April 2019 - A breast cancer support group has been told that PHARMAC has rejected funding for the drug ...
Posted by Michael Wonder on 08 Mar 2019
Decision to make changes to funded haemophilia treatments
8 March 2019 - PHARMAC is pleased to announce changes to funded haemophilia treatments that will result in two new ...
Posted by Michael Wonder on 18 Feb 2019
Decision on spinal muscular atrophy treatment Spinraza deferred
18 February 2019 - PHARMAC's decision to defer a decision on funding the only treatment for spinal muscular atrophy (SMA) ...
Posted by Michael Wonder on 14 Feb 2019
OIA responses: exploring ways to publish them
14 February 2019 - To support New Zealand's commitment to open government, PHARMAC is exploring ways to publish more of ...
Posted by Michael Wonder on 06 Feb 2019
Comparing PHARMAC's outcomes with those of Australia
7 February 2019 - New Zealand's Prime Minister Jacinda Ahern's claim that is unfair to compare PHARMAC's outcomes with those ...
Posted by Michael Wonder on 31 Jan 2019
Decision to open access to atomoxetine and change funded brand
31 January 2019 - PHARMAC is pleased to announce that all funding restrictions on atomoxetine will be removed from 1 ...
Posted by Michael Wonder on 29 Jan 2019
Proposal for changes to funded haemophilia treatments
29 January 2019 - PHARMAC is proposing to make changes to the funding of haemophilia treatments from 1 May 2019, ...